244 related articles for article (PubMed ID: 23893242)
1. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
[TBL] [Abstract][Full Text] [Related]
2. Scaffold attachment factor B1: an intrinsic inhibitor of androgen receptor downregulated in prostate cancer.
Huang H
Asian J Androl; 2013 Nov; 15(6):703-4. PubMed ID: 24077602
[TBL] [Abstract][Full Text] [Related]
3. FUS interacts with nuclear matrix-associated protein SAFB1 as well as Matrin3 to regulate splicing and ligand-mediated transcription.
Yamaguchi A; Takanashi K
Sci Rep; 2016 Oct; 6():35195. PubMed ID: 27731383
[TBL] [Abstract][Full Text] [Related]
4. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.
Bohrer LR; Chen S; Hallstrom TC; Huang H
Endocrinology; 2010 Nov; 151(11):5136-45. PubMed ID: 20881251
[TBL] [Abstract][Full Text] [Related]
5. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
Jiang S; Meyer R; Kang K; Osborne CK; Wong J; Oesterreich S
Mol Endocrinol; 2006 Feb; 20(2):311-20. PubMed ID: 16195251
[TBL] [Abstract][Full Text] [Related]
6. SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells.
Hammerich-Hille S; Kaipparettu BA; Tsimelzon A; Creighton CJ; Jiang S; Polo JM; Melnick A; Meyer R; Oesterreich S
J Biol Chem; 2010 Feb; 285(6):3608-3616. PubMed ID: 19901029
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
8. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal antibody raised against human EZH2 cross-reacts with the RNA-binding protein SAFB.
Cherney RE; Mills CA; Herring LE; Braceros AK; Calabrese JM
Biol Open; 2023 Jun; 12(6):. PubMed ID: 37283223
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
11. Co-repressor activity of scaffold attachment factor B1 requires sumoylation.
Garee JP; Meyer R; Oesterreich S
Biochem Biophys Res Commun; 2011 May; 408(4):516-22. PubMed ID: 21527249
[TBL] [Abstract][Full Text] [Related]
12. Enhancer of rudimentary homologue interacts with scaffold attachment factor B at the nuclear matrix to regulate SR protein phosphorylation.
Drakouli S; Lyberopoulou A; Papathanassiou M; Mylonis I; Georgatsou E
FEBS J; 2017 Aug; 284(15):2482-2500. PubMed ID: 28627136
[TBL] [Abstract][Full Text] [Related]
13. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
[TBL] [Abstract][Full Text] [Related]
14. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
[TBL] [Abstract][Full Text] [Related]
15. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
[TBL] [Abstract][Full Text] [Related]
16. Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity.
Debril MB; Dubuquoy L; Feige JN; Wahli W; Desvergne B; Auwerx J; Gelman L
J Mol Endocrinol; 2005 Dec; 35(3):503-17. PubMed ID: 16326836
[TBL] [Abstract][Full Text] [Related]
17. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
Wang HJ; Pochampalli M; Wang LY; Zou JX; Li PS; Hsu SC; Wang BJ; Huang SH; Yang P; Yang JC; Chu CY; Hsieh CL; Sung SY; Li CF; Tepper CG; Ann DK; Gao AC; Evans CP; Izumiya Y; Chuu CP; Wang WC; Chen HW; Kung HJ
Oncogene; 2019 Jan; 38(1):17-32. PubMed ID: 30072740
[TBL] [Abstract][Full Text] [Related]
18. Scaffold attachment factors SAFB1 and SAFB2: Innocent bystanders or critical players in breast tumorigenesis?
Oesterreich S
J Cell Biochem; 2003 Nov; 90(4):653-61. PubMed ID: 14587024
[TBL] [Abstract][Full Text] [Related]
19. Scaffold attachment factor B1 regulates androgen degradation pathways in prostate cancer.
Yang JS; Qian C; You S; Rotinen M; Posadas EM; Freedland SJ; Di Vizio D; Kim J; Freeman MR
Am J Clin Exp Urol; 2021; 9(4):337-349. PubMed ID: 34541032
[TBL] [Abstract][Full Text] [Related]
20. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
Xu K; Wu ZJ; Groner AC; He HH; Cai C; Lis RT; Wu X; Stack EC; Loda M; Liu T; Xu H; Cato L; Thornton JE; Gregory RI; Morrissey C; Vessella RL; Montironi R; Magi-Galluzzi C; Kantoff PW; Balk SP; Liu XS; Brown M
Science; 2012 Dec; 338(6113):1465-9. PubMed ID: 23239736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
